NuPathe Submits Zelrix NDA for the Treatment of Migraine
Safeguard Scientifics’ partner company NuPathe submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The NDA was filed for ZelrixTM,…
Posted by
Safeguard Scientifics’ partner company NuPathe submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The NDA was filed for ZelrixTM,…
Posted by
Today, we were honored by the Philadelphia Business Journal with the Inaugural Life Sciences Venture Impact Award, which “goes to the venture capital firm from…
Posted by
Advances in the life sciences will continue to have a far-reaching impact on virtually every aspect of our society. There is an abundance of companies…
Posted by
On the eve of the International Conference on Alzheimer’s Disease (ICAD), Bloomberg Businessweek’s Elizabeth Lopatto and Kanoko Matsuyama reported that Avid Radiopharmaceuticals, Inc., a Safeguard…
Posted by
While there are a wealth of opportunities to deploy capital in a variety of life sciences companies, the evolution and potential long-term impact of regenerative…
Posted by
Avid Radiopharmaceuticals was featured on the front page of The New York Times today. The article, “Promise Seen for Detection of Alzheimer’s,” by Gina Kolata (@ginakolata), highlights…
Posted by
On the heels of the BIO International Convention, I came across this piece by FierceBiotech’s Maureen Martino highlighting a panel of biotech VCs who made…
Posted by
Safeguard Scientifics’ partner company Avid Radiopharmaceuticals was invited to present its technology and growth strategy at the prestigious J.P. Morgan 28th Annual Healthcare Conference in…
Posted by
Bruce Bigelow of Xconomy San Diego highlights Advanced BioHealing’s (ABH) commercial success with Dermagraft in his article. Bigelow details the success of Dermagraft and ABH’s…
Posted by